Cancer Vaccines

DeMaria, Peter J.; Bilušić, Marijo

doi:10.1016/j.hoc.2018.12.001

Cited by 107 publications

(77 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-naïve subtypes of CD8 + T cells were distributed on the left branches, including states 1, 2, 3, 7, 8, and 9 (Figure 4A and S4A). When separated based on different treatments, the cell trajectory patterns were shifted by GC and LIT from upper states (1, 2, 3, 5, 9) to lower states (6, 7, 8), as shown in Figure 4B. To determine if the shift was indeed due to T cell activation, we generated volcano plots of the top DEGs of CD8 + T cells between LIT-treated and CTRL tumors (Figure S4B).…”

Section: Resultsmentioning

confidence: 99%

“…Cancer immunotherapy, which boosts the immune response to cancer, holds high promise for treating metastatic cancers (3). Various immunotherapies, such as cytokine and monoclonal antibody therapy (4,5) adoptive cell therapy (6), chimeric antigen receptor T-cell (CAR-T) therapy (7), tumor vaccines (8), and immune checkpoint therapy (ICT) (9), represent potent anti-cancer treatments. Unfortunately, most of these treatments rely on existing antitumor immune responses or prerequisite knowledge of target tumor antigens.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

ScRNA-seq reveals tumor microenvironment remodeling induced by local intervention-based immunotherapy

Hoover

Liu

DeVette

et al. 2020

Preprint

View full text Add to dashboard Cite

Laser immunotherapy (LIT) combines local photothermal therapy (PTT), to disrupt tumor homeostasis and release tumor antigens, and an intratumorally administered immunostimulant, N-dihydrogalactochitosan (GC), to induce antitumor immune responses. We performed single-cell RNA sequencing on tumor-infiltrating leukocytes of MMTV-PyMT mouse mammary tumors to characterize LIT-induced myeloid and lymphoid compartment remodeling. Analysis of 49,380 single cell transcriptomes from different treatment groups revealed that proinflammatory IFNα, IFNγ, and TNFα cytokine signaling pathways were enriched in both lymphoid and myeloid cells isolated from LIT-treated tumors. The CD4+ and CD8+ T cells in LIT treated tumors resided in an activated state while immune cells in untreated and PTT-treated tumors remained in a neutral/resting state. Additionally, monocytes recruited into the LIT-treated tumors were driven towards proinflammatory M1-like macrophage phenotypes or monocyte-derived dendritic cells. Our results reveal that LIT prompts immunological remodeling of the tumor microenvironment by initiating broad proinflammatory responses to drive antitumor immunity.STATEMENT OF SIGNIFICANCETranscriptome profiling of tumor infiltrating leukocytes revealed that localized laser immunotherapy (LIT) greatly enhanced antitumor T cell activity by promoting proinflammatory myeloid cell responses within the tumor microenvironment. This manuscript demonstrates that LIT broadly stimulates antitumor immunity and has great potential to synergize with current immunotherapies to increase their efficacy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

ScRNA-seq reveals tumor microenvironment remodeling induced by local intervention-based immunotherapy

Hoover

Liu

DeVette

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Cancer vaccine induced immune responses exhibit unique kinetics, can target tumor neoantigens, and induce an antigen cascade [65].…”

Section: Mechanism Of Actionmentioning

confidence: 99%

Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis

Schirrmacher¹

2020

Biomedicines

View full text Add to dashboard Cite

This review compares cytotoxic drugs, targeted therapies, and immunotherapies with regard to mechanisms and side effects. Targeted therapies relate to small molecule inhibitors. Immunotherapies include checkpoint inhibitory antibodies, chimeric antigen receptor (CAR) T-cells, cancer vaccines, and oncolytic viruses. All these therapeutic approaches fight systemic disease, be it micro-metastatic or metastatic. The analysis includes only studies with a proven therapeutic effect. A clear-cut difference is observed with regard to major adverse events (WHO grades 3–4). Such severe side effects are not observed with cancer vaccines/oncolytic viruses while they are seen with all the other systemic therapies. Reasons for this difference are discussed.

show abstract

“…Therapeutic vaccines hold great promises for long-term remission in patients, in that they can install immunological memory directed against the tumor. Unfortunately, despite extensive research, only four cancer vaccines have made it into the clinic to date: two prophylactic ones, the human papilloma virus vaccine and the hepatitis B virus vaccine for prevention of cervical and liver cancer respectively, and two therapeutic ones, namely the Bacillus Calmette-Guérin (BCG) vaccine, which reduces relapse and metastasis of early stage bladder cancers, and Sipuleucel-T, a cellbased vaccine for advanced prostate cancer (DeMaria and Bilusic, 2019). Therefore, important additional efforts are required to achieve the high expectations of especially therapeutic cancer vaccines at the bedside.…”

Section: Introductionmentioning

confidence: 99%

Engineering Targeting Materials for Therapeutic Cancer Vaccines

Briquez

Hauert

Titta³

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Therapeutic cancer vaccines constitute a valuable tool to educate the immune system to fight tumors and prevent cancer relapse. Nevertheless, the number of cancer vaccines in the clinic remains very limited to date, highlighting the need for further technology development. Recently, cancer vaccines have been improved by the use of materials, which can strongly enhance their intrinsic properties and biodistribution profile. Moreover, vaccine efficacy and safety can be substantially modulated through selection of the site at which they are delivered, which fosters the engineering of materials capable of targeting cancer vaccines to specific relevant sites, such as within the tumor or within lymphoid organs, to further optimize their immunotherapeutic effects. In this review, we aim to give the reader an overview of principles and current strategies to engineer therapeutic cancer vaccines, with a particular focus on the use of sitespecific targeting materials. We will first recall the goal of therapeutic cancer vaccination and the type of immune responses sought upon vaccination, before detailing key components of cancer vaccines. We will then present how materials can be engineered to enhance the vaccine's pharmacokinetic and pharmacodynamic properties. Finally, we will discuss the rationale for site-specific targeting of cancer vaccines and provide examples of current targeting technologies.

show abstract

Cancer Vaccines

Cited by 107 publications

References 58 publications

ScRNA-seq reveals tumor microenvironment remodeling induced by local intervention-based immunotherapy

ScRNA-seq reveals tumor microenvironment remodeling induced by local intervention-based immunotherapy

Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis

Engineering Targeting Materials for Therapeutic Cancer Vaccines

Contact Info

Product

Resources

About